HCM
HUTCHMED (China) Limited
There isn't enough reported data to score HCM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HCM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
HCM's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HCM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.1x | $2.63 | -82% |
| Current | 5.7x | $14.85 | — |
| Fair | 5.8x | $3.00 | -80% |
| Expensive | 67x | $34.83 | +135% |
Historical ranges are pointers, not guarantees.
HCM's PE is 5.7x, but its earnings don't support one, so it isn't a reliable read right now.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over HCM in the historical PE scenario, which offers more potential upside but is not a forecast.
HCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect HCM's losses to grow, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.52 | +1200% |
| Q2 2025 | $0.53 | +$0.57 |
| Q4 2024 | $0.04 | -67% |
| Q2 2024 | -$0.04 | +$0.01 |
| Q4 2023 | $0.12 | +$0.55 |
| Q2 2023 | -$0.05 | +$0.25 |
| Q4 2022 | -$0.43 | -$0.18 |
| Q2 2022 | -$0.30 | -$0.05 |
HCM has the edge over NVO in the latest year-over-year earnings comparison.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
HCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $270.8M | -17% |
| Q2 2025 | $277.7M | -9.2% |
| Q4 2024 | $324.5M | +6.4% |
| Q2 2024 | $305.7M | -43% |
| Q4 2023 | $305.1M | +36% |
| Q2 2023 | $532.9M | +164% |
| Q4 2022 | $224.4M | +13% |
| Q2 2022 | $202M | +28% |
HCM's revenue has slid since its 2023 peak: $271M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +17 points |
| Q2 2025 | -1.3% | -22 points |
| Q4 2024 | -5% | +89 points |
| Q2 2024 | -9% | +88 points |
| Q4 2023 | -31% | +62 points |
| Q2 2023 | 21% | +112 points |
| Q4 2022 | -94% | +3.8 points |
| Q2 2022 | -97% | -24 points |
HCM's operating margin was −13% last quarter, up 17 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over HCM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
HCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.4M | -90% |
| Q2 2025 | -$82.2M | -$32.2M |
| Q4 2024 | $32.5M | +$47.9M |
| Q2 2024 | -$49.9M | -125% |
| Q4 2023 | -$15.4M | +$184.3M |
| Q2 2023 | $202M | +$307.7M |
| Q4 2022 | -$199.7M | -$59.3M |
| Q2 2022 | -$105.6M | -$25.4M |
HCM has burned cash in most quarters: −$96M over the past year, against −$119M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
HCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +327K shares |
| 1 year | +0.4% | +3.7M shares |
| 3 years | +31% | +207M shares |
| 5 years | +46% | +273M shares |
HCM has 873M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $36.1M |
| Q4 2023 | — |
| Q2 2023 | $9.1M |
| Q4 2022 | — |
| Q2 2022 | $48.1M |
| Q4 2021 | $551,000 |
| Q2 2021 | $26.8M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over HCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -6.5x | Net Cash |
HCM has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
HCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 79.2 | Neutral |
HCM's weekly RSI is 59 (neutral) and its Stochastic is 79 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HCM PE vs Healthcare Sector
| Metric | HCM | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 46 | 29 | 17 pts above |
HCM has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.2 | 4.4% above |
| 20 week MA | $13.0 | 14% above |
| 50 week MA | $13.4 | 11% above |
| 100 week MA | $14.3 | 4% above |
| 200 week MA | $15.4 | 3.8% below |
HCM has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
HCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $29.5 | +16% |
| 2021 | $29.5 | $35.3 | +20% |
| 2022 | $35.3 | $14.0 | -60% |
| 2023 | $14.0 | $18.1 | +29% |
| 2024 | $18.1 | $14.3 | -21% |
| 2025 | $14.3 | $13.8 | -3.5% |
| 2026 YTD | $13.8 | $14.9 | +7.8% |
HCM has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.